Purpose: To evaluate clinical, immunological, and virological outcomes after first-line highly active antiretroviral therapy (HAART) with a regimen including either efavirenz (EFV) or lopinavir/ritonavir (LPV/r) in treament-naive adult patients in routine clinical care. Method: An ongoing prospective, observational follow-up study included all patients starting their first antiretroviral therapy (ART) with any of the studied regimens from July 1998 to July 2004. The follow-up period was finalized in September 2006, when all patients completed an observation of at least 96 weeks. Mortality rates, CD4 counts, viral suppression (HIV RNA below 50 copies/mL), and discontinuation of any component of the regimen were compared at 48 and 96 weeks. Results: Despite the worst immunological status of the LPV/r group patients at baseline, this regimen was at least as effective as the one based on EFV not only in terms of treatment durability but also in terms of virological responses, nevertheless with an apparently quicker immune recovery. In general terms, both regimens present similar tolerability and safety outcomes except for the higher risk of increasing triglyceride (TG) levels in the LPV/r group. Low durability was observed in both regimens. Conclusion: In a routine clinical care setting, initial HAART containing LPV/r seems to present an effectiveness, tolerability, and toxicity similar to the one containing EFV.
Introduction
Antiretroviral therapy (ART) has changed the evolution of HIV infection from a subacute mortal disease to a chronic, outpatient, long-term survival disease. 1, 2 The primary goal of ART is to achieve and maintain a nondetectable viral load using, if possible, ultrasensitive technology (<50 copies/mL) 3 ; this minimizes the immunological and clinical impairment risk and the probability of resistance development. 4, 5 Currently, Spanish, 6 British, 7 European, 8 and American 9 HIV guidelines establish that an initial ART regimen must include 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse transcriptase inhibitor (NNRTI) or 2 NRTIs and 1 protease inhibitor (PI) boosted with ritonavir (RTV). Among the preferred and recommended drugs are efavirenz (EFV), lopinavir/ritonavir (LPV/r), fosamprenavir/r, atazanavir (ATV)/r, saquinavir (SQV)/r, and darunavir/r. The final decision of choosing an NNRTI or a boosted PI to initiate treatment will depend on the clinic and personal individual characteristics, as well as the advantages or disadvantages that these drugs may have on the patient (efficacy, safety profile, high genetic barrier, administration complexity, etc).
Recently, 2 randomized clinical trials (RCTs), comparing EFV and LPV/r in treatment-naive patients, have been published. No statistically significant differences were found between the drug groups. 10 The second study demonstrates higher virological efficacy in the EFV þ 2 NRTIs group has 1 Department of Infectious Diseases, Hospital Ramó n & Cajal, Madrid, Spain.
shown a better immunological response in the LPV/r þ 2 NRTIs group, and a higher genetic barrier of this PI. 11 Although RCTs are clearly the gold standard for determining safety and efficacy of all new drugs, they are limited in the insights they can provide into the effectiveness of drugs once they are on the market. In practice, medicines are used in a wide variety of individuals who would have been excluded from the clinical trials because of restrictive inclusion and exclusion criteria (age, comorbidities, concomitant medication, etc). 12 Thus, the purpose of this article is to present the clinical outcome in a series of 188 treatment-naive, HIV-1-infected patients who started EFV-or LPV/r-based ART, with a large representation of hepatitis C virus (HCV) coinfection and drug abuse as the route of HIV infection.
The primary goal of this study was to evaluate, during routine care of patients, the virological and immunological effectiveness of EFV-or LPV/r-based ART. The other important objective was to evaluate the toxicity and tolerability related to each ART regimen, focusing on the lipid profile and hepatic toxicity. Finally, durability and resistance development associated with viral failure were evaluated.
Methods

Study Participants and Design
This research is a single-center, observational, prospective, nonrandomized, comparative follow-up ongoing clinical study of 2 antiretroviral (ARV) regimens for the initial treatment of HIV infection. All HIV-1-infected adults in whom ART with 2 NRTIs þ LPV/r or NRTIs þ EFV was prescribed, between July 1998 and July 2004, in a specialized outpatient clinic of a tertiary center were followed. The medical record of the included patients must contain at least 1 visit history providing CD4 count and an evaluation of viral load 3 months after ART initiation. The study follow-up was censored on September 30, 2006, when the last patient completed an observation period of at least 96 weeks.
Treatment and Assessments
The evaluated drug regimens were taken orally. The individual components were taken according to the patient information leaflet: EFV 600 mg once-daily (QD), preferably before going to bed and soft-gel capsule (SGC) of LPV/r 400/100 mg twicedaily (BID) with or without food. ART was individualized depending on calendar availability, international and national guidelines, and patient characteristics and preferences. This study was reviewed and approved by the Hospital Ramón & Cajal Ethical Committee (Madrid Spain). Patients gave informed consent before participating in this ongoing followup study.
The routine care of patients consisted of clinic visits every 3 to 6 months. All decisions pertaining to the medical management of the patients were the responsibility of the caregiver. At the start and during follow-up, basic demographic data and data on the presence/absence of AIDS-defining illness, risk practices, HCV coinfection, ART treatment changes, toxicity, tolerability, and adherence to treatment were collected. Adherence to treatment was evaluated by direct questioning and cross-checking with the dispensation database kept at the hospital pharmacy office. A patient was considered noncompliant if he or she took less than 90% of the prescribed doses at any time. The main virological outcome was the proportion of patients achieving successful virological response (HIV-1 RNA <50 copies/mL), while on initial treatment, at 48 and 96 weeks after treatment onset, measured by an ultrasensitive test (branched DNA version 3.0, Bayer Diagnostic, Tarrytown, New York). Other laboratory data included leukocyte, lymphocyte, platelets, hemoglobin, and other biochemical values: total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), TGs, glucose, g-glutamyl transpeptidase (GGT), alanine aminotranferase (ALT), and creatinine. In addition, at baseline visit, the results showing the presence of antibodies to the HCV were available.
Statistics
The proportion of patients achieving successful virological response was analyzed in an intention-to-treat (ITT) population comprising all follow-up data with missing cases, and those who switched from EFV or LPV/r therapy were considered failures. Continuous variables were compared using Student t test for variables with normal distribution and using Mann-Whitney or Wilcoxon test for continuous variables with unequal variances or nonnormal distribution. Categorical data were assessed with the w 2 test or the Fisher exact test. A logistic regression analysis was constructed to investigate factors influencing TGs elevation. P < .05 was considered statistically significant.
The time on initial treatment was described by means of the Kaplan-Meier method and compared between groups using a log-rank test. A multiple binomial logistic regression model with backward stepwise elimination was constructed to investigate the independent association of each baseline variable (baseline viral load, baseline CD4 count, sex, prior AIDS diagnosis, adherence to an initial virological outcome) with a successful virological outcome (HIV RNA <50 copies/mL) at 48 and 96 weeks. Explicative variables included were treatment group, definitive AIDS diagnosis, intravenous (IV) drug history, and CD4 count prior to treatment.
Results
Patient Characteristics and Disposition
Between July 1998 and July 2004, a total of 188 patients were included in the current analysis. From that patient group, 117 received EFV-based highly active antiretroviral therapy (HAART) and the remaining received LPV/r-based HAART. The baseline characteristics were similar between these 2 groups, with the exception of the proportion of diagnoses of AIDS-defining illness; this was greater among patients receiving an LPV/r regimen, and the mean baseline CD4 count was lower in this group (Table 1) .
Effectiveness
There were no significant differences between groups in virological response (Figure 1 ). The average viral load, that were significantly higher at baseline in the LPV/r group (Table 1) In the logistic regression analysis controlled by the presence of previous treatment, AIDS diagnoses, IV drug-addiction history, and pretreatment CD4 count, no factor was found to be associated with a better virological response either at 48 or at 96 weeks (data not shown).
At 96 weeks, 86 (74%) EFV group patients interrupted some component of their ARV regimen; an identical proportion (74%) was found in the LPV/r group. NRTIs were changed in 73 patients (62%) in the EFV group and 50 (70%) patients in the LPV/r group (P ¼ not significant [NS] ). At 48 and 96 weeks, considering only EFV or LPV/r, 49 (42%) and 61 (52%) patients interrupted treatment in the EFV group compared with 35 (49%) and 46 (65%) patients in the LPV/r group (P ¼ NS), time to treatment change between both groups (log rank; P ¼ .1191) ( Figure 2) .
The most important reason for treatment interruption, in both groups ( In both groups, immunological response was achieved in all visits from baseline, and the average increase in CD4 T cells was 121 versus 140 cells/mm 3 (P ¼ 0.28) at week 24, 160 versus 181 cells/mm 3 (P ¼ 0.37) at week 48, and 221 versus 296 cells/mm 3 (P ¼ .15) at week 96 in the EFV and LPV/r groups.
The absolute CD4 count (Figure 3 ), during the complete follow-up period, shows significant differences between both groups at baseline (LPV/r patients presented a lower CD4 count). This difference disappeared throughout the follow-up period due to the relatively higher CD4 increase in the LPV/r group. Two patients died during the 96-week follow-up study-1 in each treatment group (0.9% EFV vs 1.4% LPV/r, P ¼ .72). Table 3 summarizes the most frequent adverse events (those considered possible or probably related to the study medication) during the 96-week follow-up. Diarrhea was the most frequent adverse event in the LPV/r group (7%), meanwhile the central nervous system (CNS)-related symptoms were more frequent in the EFV group (6.7%). Lipodystrophy caused treatment changes in 2.8% of LPV/r patients and in 5.1% in EFV patients.
Safety and Tolerability
At week 48, no statistically significant differences were found between groups regarding the percentage of patients with total cholesterol >240 mg/mL (23% EFV vs 5% LPV/r) or percentage of patients with >160 mg/mL LDL-C (35% EFV vs 15% LPV/r).
A lower percentage of patients presented with HDL-C <40 in the LPV/r group compared to the EFV group (58% vs 20%, P ¼ .02). In a multivariate analysis based on the independent variables, that include study treatment, only stavudine (d4T) use was identified as independent variable to present those HDL-C levels, whereas treatment EFV or LPV/r (OR 6.25, 95% CI 1.28-33.3) was not.
In a multivariate analysis, patients receiving LPV/r had a higher probability of presenting with TG level above 200 mg/dL (OR 3.48, 95% CI 1.19-10.1, P < .02). No statistically significant differences were found when a higher cutoff (>500 mg/dL) was used.
Percentage of patients requiring treatment with lipidlowering agents was 7% for EFV and 9% for LPV/r groups (P ¼ NS). A very small proportion of patients required a treatment change due to metabolic disorders (1% EFV vs 4% LPV/r; P ¼ NS). Percentages of patients with ALT levels >40 U/L were similar in both groups, during the first 48 study weeks.
Resistance
Paired genotype at baseline and at failure were available in 9 EFV and in 10 LPV/r patients. None of them showed mutations associated with resistance at baseline. At the time of failure, 7 of 9 patients (78%) in the EFV group with baseline genotype presented with NNRTI and NNRTI resistance. However, the development of genotypic resistance was not seen among patients failing LPV/r. Mutations associated with the loss of PI's sensitivity (47L and 54V) were found in 2 patients.
Discussion
The results of this observational, prospective, clinical study may suggest that, in treatment-naive ART patients and in clinical practice, the efficacy, durability, and tolerability of LPV/r-based ART could be very similar to an EFV-based ART. At baseline, patients groups were not homogeneous. Patients on LPV/r-based ART had a lower CD4 count, a higher viral load, and an increased number of AIDS-defining diseases. A worse immunological situation of patients starting an LPV/r regimen has also been reported in nonrandomized studies comparing EFV-with LPV/r-based regimens. [13] [14] [15] Despite the differences, similar virological responses were found in both groups after 96 weeks of follow-up.
Evaluating treatment effects in observational studies is associated with a fact known as confounding by indication, 16 because there is always a reason for prescribing a specific drug or treatment regimen. However, despite their limitations, observational studies are a better representative of daily care practices. In clinical trials, patients on ART seem to be more adherent to treatment and may have a better immunological response compared to daily care routine; thus, they could in some way overestimate treatment efficacy. 17 Despite the more compromised immunological-clinical baseline conditions of the LPV/r patient group, our study suggests that the effectiveness of a LPV/r-based ART is, in terms of treatment durability, as well as virological, and immunological results, at least as effective as the one EFV-containing ART.
In our study, the percentage of patients that interrupted the treatment, at 48 weeks, was similar in both groups (49% LPV/r vs 42% EFV) and the rate of treatment discontinuation in the LPV/r group is higher than that observed in other studies. In a comparative nelfinavir (NFV) versus LPV/r clinical trial, about 17% of the patients in the LPV/r arm discontinued the study during a 48-week follow-up period. 18 These dissimilar data may be explained once again by the difference in the worst results in daily practice when compared to clinical trials. 17 In another observational study that compares EFV and LPV/r regimens, a mean follow-up of 17 months showed a similar therapy interruption or change rate between groups (22%). 13 Nevertheless, in other observational, noncomparative studies, the therapy discontinuation rate ranged between 36% and 45%, depending on baseline CD4 count. [19] [20] [21] The reason for this treatment interruption difference between daily practices and clinical trials could be explained by an actual tendency of regimen simplification, specially regarding NRTI substitution. 22 In our study, virological response was slightly less than those previously reported in RCTs. In a comparative EFV versus LPV/r 18 clinical trial, at week 48, greater proportions of patients treated with LPV/r than that treated with NFV had fewer than 50 copies/mL (67% vs 52%, P < .001). In our study, 49% of patients achieved <50 copies/mL, but it could be influenced by the higher proportion of patients that switched treatment as mentioned above. Very important is the fact that no significant difference in virological response was found between the LPV/r and EFV groups, neither in the raw analysis nor in the logistic regression. This result differs from that of the AIDS Clinical Trials Group (ACTG) 5142. 11 In this study, combination of EFV þ 2 NNRTIs had a significantly greater virological response than LPV/r þ 2 NRTIs (89% vs 77% at week 96). However, a significant increase in CD4 count was found in the LPV/r arm versus EFV at week 96 (268 cells/ mm 3 vs 220 cells/mm 3 , respectively).
In our study, the greater increase in CD4 count at the end of the follow-up period in the LPV/r group eliminated the differences found at study initiation. This better immune recovery observed in LPV/r versus EFV groups was also confirmed in other nonrandomized studies. [12] [13] [14] Another 2 observational studies have also shown a significantly quicker and greater CD4 increase. 13, 15 Although the sample size was not large enough to draw a firm conclusion about the potential advantages of LPV/r, our result trends were similar to those observed in RCTs. 11 The tolerability profile in both groups was similar to those reported previously. The proportion of patients that abandon treatment due to lipoatrophy was 2 times higher in the EFV group compared to the LPV/r group, despite the higher use of d4T among patients taking the PI. Regarding metabolic toxicity, a greater risk of hypertriglyceridemia was found in the LPV/r group when compared with the EFV group; however, other metabolic parameters were similar in both regimens. Short-term clinical implications of this higher risk seem limited because of the small proportion of patients requiring lipidlowering agents or ART discontinuation during the study period.
No differences were found in liver function assessment between the groups, despite the fact that higher toxicity has been found among patients taking NNRTIs when compared with those taking LPV/r, especially in those patients with advanced fibrosis. 23 Information on resistance was not systematically collected in this study, but data clearly showed the same results as in ACTG 5142, with higher frequency of resistance development in EFV-based regimen. 11 The data presented here have obvious limitations, such as the observational, nonrandomized design, and the sample size. In addition, although the observation covered more than 2 years, data came from a single site, which could limit the generalization of results.
Conclusion
In daily clinical practice, LPV/r-or EFV-based HAART seems to present a similar effectiveness, tolerability, safety, and durability with a higher hypertriglyceride risk in the LPV/r group. No virological or immunological advantage was found between groups, except for a possible quicker CD4 recovery in the LPV/ r group, which was also reported in other previous studies. A low durability was observed in both regimens. Investigaciones Sanitarias, FIS; Red Temática Cooperativa de Investigación en SIDA, groups network number 173 and R_MBE).
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